- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
Patent holdings for IPC class A61P 31/16
Total number of patents in this class: 3279
10-year publication summary
|
97
|
86
|
139
|
226
|
233
|
369
|
379
|
325
|
272
|
16
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Shionogi & Co., Ltd. | 889 |
43 |
| Novartis AG | 11254 |
26 |
| Medicago Inc. | 179 |
24 |
| University of Rochester | 1276 |
22 |
| Glaxosmithkline Biologicals S.A. | 1696 |
21 |
| Sunshine Lake Pharma Co., Ltd. | 570 |
21 |
| Sanofi | 3951 |
21 |
| F. Hoffmann-La Roche AG | 7942 |
20 |
| Academia Sinica | 915 |
20 |
| Humabs Biomed SA | 123 |
20 |
| Janssen Vaccines & Prevention B.V. | 334 |
20 |
| Regeneron Pharmaceuticals, Inc. | 3986 |
20 |
| Cocrystal Pharma, Inc. | 45 |
18 |
| Intervet Inc. | 872 |
18 |
| Emory University | 1588 |
17 |
| Icahn School of Medicine at Mount Sinai | 905 |
17 |
| Intervet International B.V. | 1283 |
17 |
| MedImmune, LLC | 488 |
17 |
| Modernatx, Inc. | 1206 |
17 |
| VIR Biotechnology, Inc. | 132 |
17 |
| Other owners | 2863 |